**Biology**

LLUCC-BIOSPECIMEN LABORATORY - SPECIMEN COLLECTION  
Loma Linda University Cancer Center Biospecimen Laboratory Specimen Collection  
C.S. Chen, M.D., Ph.D.

Radiation Medicine  
Cytogenetic damage as a biomarker of radiation sensitivity in prostate cancer  
Marcelo Vasquez, MD, PhD

**Breast**

SWOG-S1007  
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer  
Gayathri Nagaraj, M.D.  
http://www.clinicaltrials.gov/ct2/show/NCT01272037

SWOG-S1207  
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of EVEROLIMUS in Patients with High-Risk Hormone Receptor-Positive and HER2/neu Negative Breast Cancer  
Gayathri Nagaraj, M.D.  
http://www.clinicaltrials.gov/ct2/show/NCT01674140

SWOG-A011106  
ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study  
Gayathri Nagaraj, M.D.  
https://clinicaltrials.gov/ct2/show/NCT01953588

NSABP-B52  
A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) with or Without Estrogen Deprivation  
Gayathri Nagaraj, M.D.  
https://clinicaltrials.gov/ct2/show/NCT02003209

SWOG-A011202  
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy  
Sharon Lum, M.D.  
https://clinicaltrials.gov/ct2/show/NCT01901094

**GI Colon**

SWOG-S0820  
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)  
Chung-Tsuen Hsueh, M.D., Ph.D.  
http://www.clinicaltrials.gov/ct2/show/NCT01349881
<table>
<thead>
<tr>
<th><strong>GI</strong></th>
<th><strong>Esophagus</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiation Medicine</td>
<td>A phase II trial of proton-chemotherapy (PCT) for resectable esophageal or esophagogastric junction cancer</td>
</tr>
<tr>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT01684904">https://clinicaltrials.gov/ct2/show/NCT01684904</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>GI</strong></th>
<th><strong>Liver</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiation Medicine</td>
<td>Randomized controlled trial of transarterial chemoembolization versus proton beam radiotherapy for the treatment of hepatocellular carcinoma</td>
</tr>
<tr>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT00857805">https://clinicaltrials.gov/ct2/show/NCT00857805</a></td>
</tr>
<tr>
<td>Radiation Medicine</td>
<td>Randomized controlled trial of proton beam radiotherapy plus Sorafenib vs Sorafenib for patients with hepatocellular carcinoma exceeding San Francisco criteria</td>
</tr>
<tr>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT01141478">https://clinicaltrials.gov/ct2/show/NCT01141478</a></td>
</tr>
<tr>
<td>Radiation Medicine</td>
<td>Phase I/II Trial of Stereotactic Body Proton Therapy (SBPT) for Patients with Liver Metastases</td>
</tr>
<tr>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT01697371">https://clinicaltrials.gov/ct2/show/NCT01697371</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>GI</strong></th>
<th><strong>Pancreas</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiation Medicine</td>
<td>A phase II trial of gemcitabine and erlotinib (GB) plus proton-chemotherapy (PCT) and capox for locally advanced pancreatic cancer (LAPC)</td>
</tr>
<tr>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT01683422">https://clinicaltrials.gov/ct2/show/NCT01683422</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>GU</strong></th>
<th><strong>Prostate</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SWOG-S1216</td>
<td>A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer</td>
</tr>
<tr>
<td>Radiation Medicine</td>
<td>Phase I-II trial of hypofractionated conformal proton beam radiation therapy for favorable-risk prostate Cancer</td>
</tr>
<tr>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT00831623">https://clinicaltrials.gov/ct2/show/NCT00831623</a></td>
</tr>
</tbody>
</table>
Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050

Adult Open Studies

**Dermatologic Toxicities**

SWOG-S1013  
A Prospective Study of Epidermal Growth Factor Receptor (HER-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy - EGFR18 (FACT-EGFRI 18) Questionnaire for EGFR-Induced Skin Toxicities  
http://www.clinicaltrials.gov/ct2/show/NCT01416688

**GYN**

GOG-0277  
A Phase III Randomized Trial of Gemcitabine (NSC # 613327) plus Docetaxel (NSC # 628503) followed by Doxorubicin (NSC # 123127) versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma  
http://clinicaltrials.gov/ct2/show/NCT01533207

GOG-0275  
A Phase III Randomized Trial of Pulse Actinomycin-D versus Multi-Day Methotrexate for The Treatment of Low-Risk Gestational Trophoblastic Neoplasia  
https://clinicaltrials.gov/ct2/show/NCT01355053

GOG-0263  
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy  
https://clinicaltrials.gov/ct2/show/NCT01101451

**Lung**

CALGB-140503  
A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (d2 cm) Peripheral Non-Small Cell Lung Cancer  
http://www.clinicaltrials.gov/ct2/show/NCT00499330

CALGB-30901  
Randomized Phase II Study of Maintenance Pemetrexed versus Observation for Patients with Malignant Pleural Mesothelioma Without Progression After First-line Chemotherapy  
http://www.clinicaltrials.gov/ct2/show/NCT01085630

SYNTA-9090-14  
A Randomized, Phase 3 Study of Ganetespib in Combination with Docetaxel versus Docetaxel Alone in Patients with Advanced Non-Small-Cell Lung Adenocarcinoma  
https://clinicaltrials.gov/ct2/show/NCT01798485

SWOG-S1400  
Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer  
http://clinicaltrials.gov/ct2/show/NCT02154490  
***Sub-Study E only is permanently closed to enrollment effective 11/25/14

SWOG-A151216  
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)  
https://clinicaltrials.gov/ct2/show/NCT02194738
**Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050**

### Adult Open Studies

**SWOG-A081105**  
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)  
https://clinicaltrials.gov/ct2/show/NCT02194738

**SWOG-E4512**  
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein  
https://clinicaltrials.gov/ct2/show/NCT02201992

**AstraZeneca-D5160C00003**  
A Phase III, Open Label, Randomized Study of AZD9291 versus Platinum-Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene (AURA3)  
https://clinicaltrials.gov/ct2/show/NCT02151981

**Eli Lilly & Co-I3Y-MC-JPBK**  
JUNIPER: A Randomized Phase 3 Study of Abemaciclib plus Best Supportive Care versus Erlotinib plus Best Supportive Care in Patients with Stage IV NSCLC with a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy  
https://clinicaltrials.gov/ct2/show/NCT02152631

**Novartis-CLDK378A2112**  
A multi-center, randomized open label study to assess the systemic exposure, efficacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)  
https://clinicaltrials.gov/ct2/show/NCT02299505

### Lymphoma

**SWOG-E1412**  
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma  
http://clinicaltrials.gov/ct2/show/NCT01856192

### Melanoma

**SWOG-S1320**  
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma  
http://clinicaltrials.gov/ct2/show/NCT02196181

### Multiple

**BCT-BCT-100-005**  
Recombinant Human Arginase 1 (rhArg1) in Patients with Advanced, Arginine Auxotrophic Solid Tumors: Dose Escalation, Safety, and PK/PD  
https://clinicaltrials.gov/ct2/show/NCT02285101

---

08/10/2015
## Soft Tissue Sarcoma

<table>
<thead>
<tr>
<th>Department</th>
<th>Description</th>
<th>Principal Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiation Medicine</td>
<td>A phase II study of preoperative proton therapy in soft tissue sarcomas of the extremities and body wall</td>
<td>Gary Yang, MD</td>
</tr>
<tr>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT01819831">https://clinicaltrials.gov/ct2/show/NCT01819831</a></td>
<td></td>
</tr>
</tbody>
</table>

## Registry

<table>
<thead>
<tr>
<th>Department</th>
<th>Description</th>
<th>Principal Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiation Medicine</td>
<td>Radiation Medicine Patient Registry</td>
<td>Jerry D. Slater, MD</td>
</tr>
<tr>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02436941">https://clinicaltrials.gov/ct2/show/NCT02436941</a></td>
<td></td>
</tr>
</tbody>
</table>